University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.

Bubb, KJ, Trinder, SL, Baliga, RS, Patel, J, Clapp, LH, MacAllister, RJ and Hobbs, AJ (2014) Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation, 130 (6). pp. 496-507.

Full text not available from this repository.

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disorder characterized by increased pulmonary artery pressure, remodeling of the pulmonary vasculature, and right ventricular failure. Loss of endothelium-derived nitric oxide (NO) and prostacyclin contributes to PH pathogenesis, and current therapies are targeted to restore these pathways. Phosphodiesterases (PDEs) are a family of enzymes that break down cGMP and cAMP, which underpin the bioactivity of NO and prostacyclin. PDE5 inhibitors (eg, sildenafil) are licensed for PH, but a role for PDE2 in lung physiology and disease has yet to be established. Herein, we investigated whether PDE2 inhibition modulates pulmonary cyclic nucleotide signaling and ameliorates experimental PH. METHODS AND RESULTS: The selective PDE2 inhibitor BAY 60-7550 augmented atrial natriuretic peptide- and treprostinil-evoked pulmonary vascular relaxation in isolated arteries from chronically hypoxic rats. BAY 60-7550 prevented the onset of both hypoxia- and bleomycin-induced PH and produced a significantly greater reduction in disease severity when given in combination with a neutral endopeptidase inhibitor (enhances endogenous natriuretic peptides), trepostinil, inorganic nitrate (NO donor), or a PDE5 inhibitor. Proliferation of pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension was reduced by BAY 60-7550, an effect further enhanced in the presence of atrial natriuretic peptide, NO, and treprostinil. CONCLUSIONS: PDE2 inhibition elicits pulmonary dilation, prevents pulmonary vascular remodeling, and reduces the right ventricular hypertrophy characteristic of PH. This favorable pharmacodynamic profile is dependent on natriuretic peptide bioactivity and is additive with prostacyclin analogues, PDE5 inhibitor, and NO. PDE2 inhibition represents a viable, orally active therapy for PH.

Item Type: Article
Authors :
NameEmailORCID
Bubb, KJUNSPECIFIEDUNSPECIFIED
Trinder, SLs.trinder@surrey.ac.ukUNSPECIFIED
Baliga, RSUNSPECIFIEDUNSPECIFIED
Patel, JUNSPECIFIEDUNSPECIFIED
Clapp, LHUNSPECIFIEDUNSPECIFIED
MacAllister, RJUNSPECIFIEDUNSPECIFIED
Hobbs, AJUNSPECIFIEDUNSPECIFIED
Date : 5 August 2014
Identification Number : https://doi.org/10.1161/CIRCULATIONAHA.114.009751
Uncontrolled Keywords : cyclic nucleotide, natriuretic peptide, nitric oxide, phosphodiesterase inhibitor, pulmonary hypertension, Animals, Cells, Cultured, Cyclic AMP, Cyclic GMP, Cyclic Nucleotide Phosphodiesterases, Type 2, Humans, Hypertension, Pulmonary, Imidazoles, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Phosphodiesterase Inhibitors, Rats, Rats, Sprague-Dawley, Signal Transduction, Triazines
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:44
Last Modified : 17 May 2017 14:52
URI: http://epubs.surrey.ac.uk/id/eprint/829049

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800